Dr. Frederick C. Raiser III, DO
Emergency Medicine (Emergency Medicine Physician)
- Medicare participating
At a glance
- Medical school
- Lake Erie College of Osteopathic Medicine, Erie (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 570
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: Lake Erie College of Osteopathic Medicine, Erie
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Emergency Medicine Physician primary
NE license 782
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The Nebraska Methodist Hospital Omaha, NE
Medical groups
- Nebraska Methodist Hospital (136 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 570
- Services billed
- 637
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Emergency department visit with high level of medical decision making | 252 | 246 |
| Emergency department visit with moderate level of medical decision making | 229 | 227 |
| Critical care, first 30-74 minutes | 58 | 57 |
| Emergency department visit with low level of medical decision making | 47 | 46 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Omaha, NE | 28 |
| Prednisone Other prescribers in Omaha, NE | 24 |
| Cephalexin Other prescribers in Omaha, NE | 22 |
| Doxycycline Hyclate Other prescribers in Omaha, NE | 15 |
| Ciprofloxacin Hcl Other prescribers in Omaha, NE | 13 |
| Ondansetron Odt (ondansetron) Other prescribers in Omaha, NE | 12 |
| Amoxicillin-Clavulanate Potass (amoxicillin/potassium clav) Other prescribers in Omaha, NE | 11 |
| Levofloxacin Other prescribers in Omaha, NE | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 31 industry-funded studies in 2025, from 10 companies. The companies reported $3,180,029 in research payments for these studies, mostly to the institutions running them.
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
Seqirus USA Inc · Completed · NCT06087640 - A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
ModernaTX, Inc. · Active, not recruiting · NCT05164094 - Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
ModernaTX, Inc. · Completed · NCT05992935 - Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
Valneva Austria GmbH · Completed · NCT06334393 - A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN.
Novavax Inc - A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
ModernaTX, Inc. · Completed · NCT05575492 - A Phase I/II, Double-blinded, Randomized, Placebo-Controlled, Dose Selection Study in Adults to Assess the Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines PANDA
AstraZeneca Pharmaceuticals LP - A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
ModernaTX, Inc. · Terminated · NCT05085366 - A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
Bavarian Nordic A/s · Active, not recruiting · NCT07003984
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.